PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses

0541770 - ÚMCH 2022 RIV CH eng J - Článek v odborném periodiku
Dölen, Y. - Gileadi, U. - Chen, J.-L. - Valente, M. - Creemers, J. H. A. - van Dinther, E. A. W. - van Riessen, N. K. - Jäger, Eliezer - Hrubý, Martin - Cerundolo, V. - Diken, M. - Figdor, C. G. - de Vries, I. J. M.
PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses.
Frontiers in Immunology. Roč. 12, February (2021), č. článku 641703. ISSN 1664-3224. E-ISSN 1664-3224
GRANT EU: European Commission(XE) 686089 - PRECIOUS
Institucionální podpora: RVO:61389013
Klíčová slova: NY-ESO-1 * iNKT cell * B cell epitope
Obor OECD: Polymer science
Impakt faktor: 8.787, rok: 2021
Způsob publikování: Open access
https://www.frontiersin.org/articles/10.3389/fimmu.2021.641703/full

Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based nanoparticle vaccine that contains both the immunogenic cancer germline antigen NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell transactivator. Three peptide sequences (85–111, 117–143, and 157–165) derived from immunodominant regions of NY-ESO-1 were selected. These peptides have a wide HLA coverage and were efficiently processed and presented by dendritic cells via various HLA subtypes. Co-delivery of IMM60 enhanced CD4 and CD8 T cell responses and antibody levels against NY-ESO-1 in vivo. Moreover, the nanoparticles have negligible systemic toxicity in high doses, and they could be produced according to GMP guidelines. Together, we demonstrated the feasibility of producing a PLGA-based nanovaccine containing immunogenic peptides and an iNKT cell agonist, that is activating DCs to induce antigen-specific T cell responses.
Trvalý link: http://hdl.handle.net/11104/0319301